Orexigen Insists Revised Contrave Data Should Not Affect Timing Of NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells the biotech corrections to secondary endpoint data for one pivotal study for its diet pill filing comprise only a clinical amendment.